EFFICIENCY OF RADIOTHERAPY TREATMENT IN PATIENTS WITH BONE METASTASES OF PROSTATE CANCER AND RENAL-CELL CANCER

Authors

  • RAKHIMOV Nodir Makhammatkulovich
  • SHAKHANOVA Shakhnoza Shavkatovna
  • KHAKIMOV Alisher Abdurakhmonovich
  • KALYUTA Tatyana Yurievna
  • VELIKANOVA Marina Gennadievna
  • ALEXANDER Korolev

Keywords:

radiation therapy, 1 53-samarium-oxabiphor, prostate cancer, kidney cancer, pain.

Abstract

Data from the World Health Organization (WHO) show that about 4 million people worldwide experience pain every day due to malignant diseases; in half of these people, discomfort due to bone metastases is the dominant source of symptoms ( Pavlova N. S., Sergienko E. A., 2020; Radbruch L., 2020 ). Most patients with bone metastases develop severe pain as the disease progresses, resulting in a significant reduction in their quality of life. In recent years, there has been a steady increase in the incidence of malignant neoplasms in all major localizations. Unfortunately, there remains a high percentage of tumors detected in stage 4 of the process in the presence of distant metastases, including bone metastases. Bone metastases have a very bad impact on the patient's quality of life. In particular, bone pain is the most common type of pain caused by cancer, which may require opiate analgesics and palliative radiotherapy for pain.  

References

Bray F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries //CA: a cancer journal for clinicians. – 2018. – Т. 68. – №. 6. – С. 394-424.

Emily C.L. Wong and Anil Kapoor Does Bone-targeted Therapy Benefit Patients with Metastatic Renal Cell Carcinoma?// Translational Oncology Vol. 13, No. 2, 2020 pp. 241–244

Mirdjalol Dehkanovich Djuraev, Nodir Maxammatkulovich Rahimov, Mavluda Nigmatovna Karimova, Shakhnoza Shavkatovna Shakhanova. Current Views On The Pathogenesis Of The Parietal-Visceral Pathway Of Gastric Cancer Metastasis. The American Journal of Medical Sciences and Pharmaceutical Research, 2021/3/31. Том 3, № 03, Р 94-103.

Shakhanova Sh Sh, MD Djuraev, NM Rakhimov, MN Karimova, AF Asatulayev. Determination Of Risk Parameters In The Detection Of Asymptomatic Bone Metastases Of Kidney And Prostate Cancer. The American Journal of Medical Sciences and Pharmaceutical Research 2021/2/28, Том 3, № 02, Р 161-174.

Shaxanova Sh Sh, Raximov N.M. Improving the combined treatment tactics of many osteogen metastases of malignant tumors of the urinary-body system. Web of Scientist: International Scientific Research Journal 2022/4/30, P 1145-1149.

Шахноза Шавкатовна Шаханова, Нодир Махамматкулович Рахимов, Файзулло Тожибоевич Корабоев. Buyrаk vа prostаtа bezi koʼplаb osteogen metаstаzlаridа dаvolаsh sаmаrаdorligini oshirish. Журнал Репродуктивного Здоровья и Уро-Нефрологических Исследований 2022/6/27, Том 3, Номер 2.

Алексеев Б.Я., Нюшко К.М., Каприн А.Д. Химиотерапия второй линии у больных кастрационно-рефрактерным раком предстательной железы. От клинических исследований к практике // ОУ. 2019. №1. – С 84-91.

Борзов К.А., Валиев А.К., Мусаев Э.Р., Кулага А.В. Выбор тактики хирургического лечения пациентов с метастазами рака почки в позвоночнике // Cаркомы костей, мягких тканей и опухоли кожи. № 2–2018. С. 21-27

Моисеенко Ф.В. Будущее системной терапии в онкоурологии: таргетная терапия и/или иммунотерапия//Практическая онкология.-2019.-№2.-С.137-143.

Шаханова Ш.Ш., Рахимов Н.М., Эсанкулова Б.С., Корабоев Ф.Т., Хакимов А.А. Осложнения таргетной терапии при лечении почечно-клеточного рака с метастазами в костях и лимфоузлах. Журнал вестник врача 2021, Том 1, Номер 2 (99), Р116-120.

Шаханова Ш.Ш., Рахимов Н.М. Мультимодальный подход к лечению множественных остеогеных метастазов рака почки и предстательной железы. Клиническая и экспериментальная онкология 2020, №4 Стр 50-56.

Published

2022-09-07